• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

化合物K在大鼠和小鼠体内的药代动力学及肠道代谢

Pharmacokinetics and Intestinal Metabolism of Compound K in Rats and Mice.

作者信息

Jeon Ji-Hyeon, Kang Bitna, Lee Sowon, Jin Sojeong, Choi Min-Koo, Song Im-Sook

机构信息

College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 41566, Korea.

College of Pharmacy, Dankook University, Cheon-an 31116, Korea.

出版信息

Pharmaceutics. 2020 Feb 3;12(2):129. doi: 10.3390/pharmaceutics12020129.

DOI:10.3390/pharmaceutics12020129
PMID:32028741
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7076525/
Abstract

We aimed to investigate the plasma concentration, tissue distribution, and elimination of compound K following the intravenous administration of compound K (2 mg/kg) in rats and mice. The plasma concentrations of compound K in mice were much higher (about five-fold) than those in rats. In both rats and mice, compound K was mainly distributed in the liver and underwent biliary excretion. There was 28.4% fecal recovery of compound K in mice and 13.8% in rats, whereas its renal recovery was less than 0.1% in both rats and mice. Relative quantification of compound K and its metabolite protopanaxadiol (PPD) in rat bile and intestinal feces indicated that the metabolism from compound K into PPD occurred in the intestine but not in the plasma. Therefore, PPD detected in the plasma samples could have been absorbed from the intestine after metabolism in control rats, while PPD could not be detected in the plasma samples from bile duct cannulated rats. In conclusion, mice and rats shared common features such as exclusive liver distribution, major excretion pathway via biliary route, and intestinal metabolism to PPD. However, there were significant differences between rats and mice in the plasma concentrations of compound K and the fecal recovery of compound K and PPD.

摘要

我们旨在研究大鼠和小鼠静脉注射化合物K(2毫克/千克)后化合物K的血浆浓度、组织分布及消除情况。小鼠体内化合物K的血浆浓度比大鼠高得多(约五倍)。在大鼠和小鼠中,化合物K主要分布于肝脏并经胆汁排泄。化合物K在小鼠粪便中的回收率为28.4%,在大鼠中为13.8%,而其在大鼠和小鼠尿液中的回收率均小于0.1%。对大鼠胆汁和肠道粪便中化合物K及其代谢产物原人参二醇(PPD)的相对定量分析表明,化合物K向PPD的代谢发生在肠道而非血浆中。因此,对照大鼠血浆样本中检测到的PPD可能是在肠道代谢后从肠道吸收的,而胆管插管大鼠的血浆样本中未检测到PPD。总之,小鼠和大鼠具有共同特征,如仅分布于肝脏、主要经胆汁途径排泄以及在肠道代谢为PPD。然而,大鼠和小鼠在化合物K的血浆浓度以及化合物K和PPD的粪便回收率方面存在显著差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e250/7076525/e212ece1a4e8/pharmaceutics-12-00129-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e250/7076525/e5058d796ed4/pharmaceutics-12-00129-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e250/7076525/7d04e8250106/pharmaceutics-12-00129-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e250/7076525/0e6709321999/pharmaceutics-12-00129-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e250/7076525/49132d1d5875/pharmaceutics-12-00129-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e250/7076525/e0a1e451696c/pharmaceutics-12-00129-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e250/7076525/85cbba6ba9d6/pharmaceutics-12-00129-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e250/7076525/11cb757186b5/pharmaceutics-12-00129-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e250/7076525/70d0905c5c10/pharmaceutics-12-00129-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e250/7076525/e3a2b3879756/pharmaceutics-12-00129-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e250/7076525/e212ece1a4e8/pharmaceutics-12-00129-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e250/7076525/e5058d796ed4/pharmaceutics-12-00129-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e250/7076525/7d04e8250106/pharmaceutics-12-00129-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e250/7076525/0e6709321999/pharmaceutics-12-00129-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e250/7076525/49132d1d5875/pharmaceutics-12-00129-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e250/7076525/e0a1e451696c/pharmaceutics-12-00129-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e250/7076525/85cbba6ba9d6/pharmaceutics-12-00129-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e250/7076525/11cb757186b5/pharmaceutics-12-00129-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e250/7076525/70d0905c5c10/pharmaceutics-12-00129-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e250/7076525/e3a2b3879756/pharmaceutics-12-00129-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e250/7076525/e212ece1a4e8/pharmaceutics-12-00129-g010.jpg

相似文献

1
Pharmacokinetics and Intestinal Metabolism of Compound K in Rats and Mice.化合物K在大鼠和小鼠体内的药代动力学及肠道代谢
Pharmaceutics. 2020 Feb 3;12(2):129. doi: 10.3390/pharmaceutics12020129.
2
Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats.17-(二甲基氨基乙基氨基)-17-去甲氧基格尔德霉素(NSC 707545)在CD2F1小鼠和Fischer 344大鼠体内的药代动力学、组织分布及代谢
Cancer Chemother Pharmacol. 2002 Jan;49(1):7-19. doi: 10.1007/s00280-001-0380-8.
3
Systematic studies on the kinetic process of 20(S)-protopanaxadiol in rats and dogs: absorption, distribution, metabolism and excretion.大鼠和犬体内20(S)-原人参二醇动力学过程的系统研究:吸收、分布、代谢和排泄
Front Pharmacol. 2024 Jun 20;15:1430780. doi: 10.3389/fphar.2024.1430780. eCollection 2024.
4
Pharmacokinetics and metabolism of the new thromboxane A2 receptor antagonist ramatroban in animals. 1st communication: absorption, concentrations in plasma, metabolism, and excretion after single administration to rats and dogs.新型血栓素A2受体拮抗剂雷马曲班在动物体内的药代动力学和代谢。首次通讯:单次给药于大鼠和犬后的吸收、血浆浓度、代谢及排泄情况
Arzneimittelforschung. 1997 Aug;47(8):928-38.
5
Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human.DOT1L抑制剂匹那托司他(EPZ-5676)在大鼠、犬和人体中的代谢与处置
Cancer Chemother Pharmacol. 2016 Jan;77(1):43-62. doi: 10.1007/s00280-015-2929-y. Epub 2015 Dec 8.
6
Pharmacokinetics of 4-acetylaminophenylacetic acid. 1st communication: absorption, distribution, metabolism and excretion in mice, rats, dogs and monkeys after single administration of 14C-labeled compound.4-乙酰氨基苯乙酸的药代动力学。首次通讯:单次给予14C标记化合物后在小鼠、大鼠、狗和猴体内的吸收、分布、代谢及排泄情况
Arzneimittelforschung. 1990 Jul;40(7):800-5.
7
NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).1-氨基-2,4-二溴蒽醌(CAS编号:81-49-2)在F344/N大鼠和B6C3F1小鼠中的NTP毒理学与致癌性研究(饲料喂养研究)
Natl Toxicol Program Tech Rep Ser. 1996 Aug;383:1-370.
8
Significant intestinal excretion, one source of variability in pharmacokinetics of COL-3, a chemically modified tetracycline.显著的肠道排泄是化学修饰四环素COL-3药代动力学变异性的一个来源。
Pharm Res. 2005 Mar;22(3):397-404. doi: 10.1007/s11095-004-1877-8.
9
Pharmacokinetics of TDP223206 following intravenous and oral administration to intact rats and intravenous administration to bile duct-cannulated rats.TDP223206在完整大鼠静脉注射和口服给药以及胆管插管大鼠静脉注射后的药代动力学。
Biopharm Drug Dispos. 2008 May;29(4):219-30. doi: 10.1002/bdd.601.
10
Intestinal handling of mercury in the rat: implications of intestinal secretion of inorganic mercury following biliary ligation or cannulation.大鼠肠道对汞的处理:胆管结扎或插管后无机汞肠道分泌的影响
J Toxicol Environ Health A. 1998 Apr 24;53(8):615-36. doi: 10.1080/009841098159079.

引用本文的文献

1
Anticancer Mechanisms of Ginsenoside Compound K: A Review.人参皂苷Compound K的抗癌机制:综述
Diseases. 2025 May 5;13(5):143. doi: 10.3390/diseases13050143.
2
Rhein: An Updated Review Concerning Its Biological Activity, Pharmacokinetics, Structure Optimization, and Future Pharmaceutical Applications.大黄酸:关于其生物活性、药代动力学、结构优化及未来药物应用的最新综述
Pharmaceuticals (Basel). 2024 Dec 10;17(12):1665. doi: 10.3390/ph17121665.
3
Mammary Cancer Models: An Overview from the Past to the Future.乳腺癌模型:从过去到未来的概述

本文引用的文献

1
Tolerability and pharmacokinetics of ginsenosides Rb1, Rb2, Rc, Rd, and compound K after single or multiple administration of red ginseng extract in human beings.人参皂苷Rb1、Rb2、Rc、Rd及化合物K在人单次或多次服用红参提取物后的耐受性和药代动力学。
J Ginseng Res. 2020 Mar;44(2):229-237. doi: 10.1016/j.jgr.2018.10.006. Epub 2018 Oct 27.
2
Tentative identification of 20()-protopanaxadiol metabolites in human plasma and urine using ultra-performance liquid chromatography coupled with triple quadrupole time-of-flight mass spectrometry.使用超高效液相色谱联用三重四极杆飞行时间质谱法对人血浆和尿液中20()-原人参二醇代谢物进行初步鉴定。
J Ginseng Res. 2019 Oct;43(4):539-549. doi: 10.1016/j.jgr.2018.03.005. Epub 2018 Apr 5.
3
In Vivo. 2025 Jan-Feb;39(1):1-16. doi: 10.21873/invivo.13800.
4
Compound K Production: Achievements and Perspectives.化合物K的生产:成就与展望
Life (Basel). 2023 Jul 14;13(7):1565. doi: 10.3390/life13071565.
5
Ginsenoside compound K ameliorates palmitate-induced atrophy in C2C12 myotubes via promyogenic effects and AMPK/autophagy-mediated suppression of endoplasmic reticulum stress.人参皂苷Compound K通过促肌生成作用以及AMPK/自噬介导的对内质网应激的抑制作用,改善棕榈酸酯诱导的C2C12肌管萎缩。
J Ginseng Res. 2022 May;46(3):444-453. doi: 10.1016/j.jgr.2021.09.002. Epub 2021 Sep 10.
6
Inhibitory Effects of Pinostilbene on Adipogenesis in 3T3-L1 Adipocytes: A Study of Possible Mechanisms.白藜芦醇对 3T3-L1 脂肪细胞成脂分化的抑制作用:可能机制的研究。
Int J Mol Sci. 2021 Dec 14;22(24):13446. doi: 10.3390/ijms222413446.
7
Effect of Lactic Acid Bacteria on the Pharmacokinetics and Metabolism of Ginsenosides in Mice.乳酸菌对小鼠体内人参皂苷药代动力学及代谢的影响。
Pharmaceutics. 2021 Sep 17;13(9):1496. doi: 10.3390/pharmaceutics13091496.
8
Improved Hygroscopicity and Bioavailability of Solid Dispersion of Red Ginseng Extract with Silicon Dioxide.二氧化硅改善红参提取物固体分散体的吸湿性和生物利用度
Pharmaceutics. 2021 Jul 4;13(7):1022. doi: 10.3390/pharmaceutics13071022.
9
PPARγ activation improves the microenvironment of perivascular adipose tissue and attenuates aortic stiffening in obesity.过氧化物酶体增殖物激活受体γ 的激活改善了血管周围脂肪组织的微环境,从而减轻了肥胖引起的主动脉僵硬。
J Biomed Sci. 2021 Mar 29;28(1):22. doi: 10.1186/s12929-021-00720-y.
Detection of 13 Ginsenosides (Rb1, Rb2, Rc, Rd, Re, Rf, Rg1, Rg3, Rh2, F1, Compound K, 20()-Protopanaxadiol, and 20()-Protopanaxatriol) in Human Plasma and Application of the Analytical Method to Human Pharmacokinetic Studies Following Two Week-Repeated Administration of Red Ginseng Extract.
检测人血浆中的 13 种人参皂苷(Rb1、Rb2、Rc、Rd、Re、Rf、Rg1、Rg3、Rh2、F1、Compound K、20()-原人参二醇和 20()-原人参三醇)及红参提取物重复给药两周后在人体药代动力学研究中的应用
Molecules. 2019 Jul 18;24(14):2618. doi: 10.3390/molecules24142618.
4
Pharmacokinetic Study of Compound K in Japanese Subjects After Ingestion of Panax ginseng Fermented by Lactobacillus paracasei A221 Reveals Significant Increase of Absorption into Blood.对日本受试者摄入经副干酪乳杆菌A221发酵的人参后化合物K的药代动力学研究表明,其血液吸收显著增加。
J Med Food. 2019 Mar;22(3):257-263. doi: 10.1089/jmf.2018.4271. Epub 2018 Dec 13.
5
Preparation of ginsenoside compound-K mixed micelles with improved retention and antitumor efficacy.制备保留和抗肿瘤效果更好的人参皂苷Compound-K 混合胶束。
Int J Nanomedicine. 2018 Jul 3;13:3827-3838. doi: 10.2147/IJN.S167529. eCollection 2018.
6
Gut microbiota-mediated pharmacokinetics of ginseng saponins.肠道微生物群介导的人参皂苷药代动力学
J Ginseng Res. 2018 Jul;42(3):255-263. doi: 10.1016/j.jgr.2017.04.011. Epub 2017 Apr 28.
7
Targeted delivery of ginsenoside compound K using TPGS/PEG-PCL mixed micelles for effective treatment of lung cancer.使用 TPGS/PEG-PCL 混合胶束靶向递送人参皂苷化合物 K 以有效治疗肺癌。
Int J Nanomedicine. 2017 Oct 17;12:7653-7667. doi: 10.2147/IJN.S144305. eCollection 2017.
8
Food and Sex-Related Impacts on the Pharmacokinetics of a Single-Dose of Ginsenoside Compound K in Healthy Subjects.食物和性别对健康受试者单剂量人参皂苷Compound K药代动力学的影响。
Front Pharmacol. 2017 Sep 13;8:636. doi: 10.3389/fphar.2017.00636. eCollection 2017.
9
Biotransformation of major ginsenosides in ginsenoside model culture by lactic acid bacteria.乳酸菌对人参皂苷模型培养物中主要人参皂苷的生物转化作用。
J Ginseng Res. 2017 Jan;41(1):36-42. doi: 10.1016/j.jgr.2015.12.008. Epub 2015 Dec 28.
10
Characterization, in Vivo and in Vitro Evaluation of Solid Dispersion of Curcumin Containing d-α-Tocopheryl Polyethylene Glycol 1000 Succinate and Mannitol.姜黄素与琥珀酸聚乙二醇1000维生素E固体分散体的表征、体内和体外评价
Molecules. 2016 Oct 17;21(10):1386. doi: 10.3390/molecules21101386.